[1] YANG C,WU H,WANG J,et al. Successful management of oc-treotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery:a case report and literature review [J]. Medicine,2017,96(36):e8017.
[2] BURGESS J R,SHEPHERD J J,GREENAWAY T M. Thyrotropino-mas in multiple endocrine neoplasia type 1(MEN-1)[J]. Austral New Zealand J Med,1994,24(6):740-741.
[3] WEBER F,MULLIGAN L M. Happy 20th anniversary MEN1:from positional cloning to gene function restoration[J]. Endocrine Related Cancer,2017,24(10):E7-E11.
[4] THOMPSON M,HOGG P,DE PAOLI A,et al. Parental multiple en-docrine neoplasia type 1 (MEN 1)is associated with increased off-spring childhood mortality[J].JClinEndocrinolMetabol,2020,105(4):e1106-e1114.
[5] DE PAOLI-ISEPPI R,PRENTICE L,MARTHICK J R,et al. Multi-ple endocrine neoplasia type 1:clinical correlates of MEN1 Gene methylation[J]. Pathology,2018,50(6):622-628.
[6] THAKKER R V,NEWEY P J,WALLS G V,et al. Clinical practice guidelines for multiple endocrine neoplasia type 1(MEN1)[J]. J Clin Endocrinol Metabol,2012,97(9):2990-3011.
[7] PERRIER N D,VILLABLANCA A,LARSSON C,et al. Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism[J]. World J surg,2002,26(8):907-913.
[8] GOUDET P,BONITHON C,COSTA A,et al. A multiple endocrine neoplasia type-1 observatory in a French-speaking area. A tool from the Endocrine Tumor study Group(GTE)[ C ]//Annales D'en-docrinologie. 2007,68(2-3):154-159.
[9] DONEGAN D,SINGH OSPINA N,RODRIGUEZ-GUTIERREZ R, et al. Long-term outcomes in patients with multiple endocrine neo-plasia type 1 and pancreaticoduodenal neuroendocrine tumours [J].Clin Endocrinol,2017,86(2):199-206.
[10] DE LAAT J M,DEKKERS O M,PIETERMAN C R C,et al. Long-term natural course of pituitary tumors in patients with MEN1:results from the DutchMEN1 Study Group(DMSG)[J]. J Clin En-docrinol Metabol,2015,100(9):3288-3296.
[11] FUENTES-FAYOS A C,GARCIA-MARTINEZ A,HERRERA-MARTINEZ A D,et al. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroen-docrine tumors[J]. Minerva Endocrinol,2019,44(2):109-128.
[12]陈适,李梅,连小兰,等.生长抑素类似物在垂体促甲状腺激 素瘤诊断和治疗中的作用 [J].中华内科杂志,2006,45(11):910-913.
[13]赵苇苇,杨叶虹,叶红英,等.垂体促甲状腺素分泌瘤20例临床分析[J].中华内科杂志,2014,53(1):19-22.
[14]范晓静,臧丽,金楠,等.垂体促甲状腺激 素分泌瘤临床特点的比较分析[J].解放军医学杂志,2017,42(7):591-596.
[15]姜晓华,蔡洁,王卫庆,等.垂体促甲状腺素瘤的临床特点与诊治分析[J].中华内分泌代谢杂志,2012,28(9):729-733.
[16] CHAIAMNUAY S,MOSTER M,KATZ M R,et al. Successful man-agement of a pregnant woman with a TSH secreting pituitary adeno-ma with surgical and medical therapy[J]. Pituitary,2003,6(2):109-113.
[17]魻ZG譈VEN S,FILIZOG姚LU N,KESIM S,et al. Physiological biodis-tribution of 68Ga-DOTA-TATE in normal subjects[J]. Mol Imag Ra-dionucl Ther,2021,30(1):39.
[18] SADOWSKI SM,MILLO C,COTTLE-DELISLE C,et al. Results of 68Gallium-DOTATATE PET/CT scanning in patients with multi-ple endocrine neoplasia type 1[J]. J Amer Coll Surg,2015,221(2):509-517.
[19] HOPE T A,BERGSLAND E K,BOZKURT M F,et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors[J]. J Nucl Med,2018,59(1):66-74.